Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 Movies That Leaving an Imprint with Inventive Innovation - 2California officials warn against foraging wild mushrooms after deadly poisoning outbreak
- 3Novo Nordisk slashes prices of popular weight loss and diabetes drugs
- 4Book excerpt: "Eat Your Ice Cream" by Ezekiel J. Emanuel, M.D.
- 5FDA approves Wegovy pill for weight loss
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- German police 'cleared path for fascists with batons,' protesters say
- Figure out how to Perceive Warnings while Looking for an Auto Collision Lawyer
- 10 Demonstrated Systems to Develop Your Internet based Business
- What do teens and tweens want for the holidays? E-bikes, gift cards and lip tints.
- 5 Different ways Macintosh is Prepared to Overwhelm Gaming, Even Against Windows
- Warning for snow and ice extended
- Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
